Clinical Trial Update: ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial ACE-Breast-03 evaluating ARX-788 for HER2-positive metastatic breast cancer; sponsor Ambrx, Inc; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARX-788

Snippet

Sponsor: Ambrx, Inc. | Conditions: HER2 Positive Metastatic Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING